Stenosis

INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader

Retrieved on: 
Monday, January 22, 2024
Patient, University, Biology, RRP, CSL Behring, Polyp, Principal, MD, Associate, Therapy, DNA, Fireside chats, TB, Stenosis, Tuberculosis, Novo Nordisk, Business administration, Johns Hopkins Hospital, Novartis, Cancer, Disease, Spasmodic dysphonia, Cyst, Johns Hopkins, Bachelor, Infection, Recurrence, MBA, Royal college, CMO, NIH, Shire (pharmaceutical company), Otorhinolaryngology, Human, Medical research, Emergent, Research, Vaccine, Oppenheimer Holdings, Laryngeal cancer, Pharmaceutical industry

PLYMOUTH MEETING, Pa., Jan. 22, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in a virtual fireside chat on the potential treatment of Recurrent Respiratory Papillomatosis (RRP). INOVIO's President and CEO, Dr. Jacqueline Shea, and Chief Medical Officer, Dr. Michael Sumner, will be joined by Dr. Simon Best, Otolaryngologist at Johns Hopkins University and a Principal Investigator in INOVIO's Phase 1/2 trial with INO-3107.

Key Points: 
  • The fireside chat, titled "RRP - Disease Treatment Dynamics & Urgent Need for Therapeutic Modalities," will take place on Wednesday, January 24, 2024, at 12:00pm ET.
  • Hartaj Singh, MBA, Managing Director of Biotechnology Equity Research at Oppenheimer & Co. Inc., will moderate the discussion.
  • He is a fellowship-trained laryngeal surgeon whose clinical interests are focused on voice and airway disorders, with a particular interest in RRP.
  • Prior to joining INOVIO, she was the CEO at Aeras, a not-for-profit organization dedicated to developing new vaccines against tuberculosis (TB).

Cleerly® Launches Cleerly® ISCHEMIA™ Solution for Heart Disease Analysis

Retrieved on: 
Tuesday, January 9, 2024
Technology, Medical Devices, FDA, Health Technology, Cardiology, Software, Radiology, Health, Artificial Intelligence, Patient, Atherosclerosis, Ischemia, Science, Food and Drug Administration, Coronary artery disease, Stenosis, FACC, Food, FESC, CCTA, CAD, Diagnosis, Medical device

Cleerly ISCHEMIA analysis software is an automated machine learning-based decision support tool, intended as a diagnostic aid for patients undergoing coronary computed tomography angiography (CCTA) analysis using Cleerly Labs software.

Key Points: 
  • Cleerly ISCHEMIA analysis software is an automated machine learning-based decision support tool, intended as a diagnostic aid for patients undergoing coronary computed tomography angiography (CCTA) analysis using Cleerly Labs software.
  • When utilized by an interpreting healthcare provider, this software in conjunction with the results of Cleerly Labs provides personalized analysis that may be useful in detecting likely ischemia associated with coronary artery disease (CAD).
  • “Cleerly ISCHEMIA is a true testament to our unwavering commitment to scientific innovation and research-backed solutions,” Dr. Min said.
  • Cleerly ISCHEMIA is a transformative addition poised to reshape the landscape of cardiac care.”
    A Category 1 CPT code is available for the work performed in association with Cleerly ISCHEMIA analysis.

InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

Retrieved on: 
Wednesday, January 3, 2024
NSPR, NuVasive, TEL, Stroke, Integra, IDE, Globus Medical, Integra LifeSciences, Orthopedic surgery, Growth, Rutgers University, Patient, Compensated emancipation, Stenosis, Employment, Syracuse University, NSO, EPS, Senior

TEL AVIV, Israel and MIAMI, Jan. 03, 2024 (GLOBE NEWSWIRE) -- InspireMD (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, announced today the appointment of medical technology executive Pete Ligotti as Executive Vice President and General Manager of North America. Mr. Ligotti brings more than 30 years of general management and commercial leadership experience to the InspireMD team.

Key Points: 
  • TEL AVIV, Israel and MIAMI, Jan. 03, 2024 (GLOBE NEWSWIRE) -- InspireMD (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, announced today the appointment of medical technology executive Pete Ligotti as Executive Vice President and General Manager of North America.
  • Mr. Ligotti brings more than 30 years of general management and commercial leadership experience to the InspireMD team.
  • Before that, he served as Vice President of Global Commercial Strategy at Smith+Nephew, and, prior to that, in various roles of increasing responsibility at Integra LifeSciences, culminating with Senior Vice President and General Manager - Extremity Orthopedics.
  • In connection with the appointment of Mr. Ligotti as Executive Vice President and General Manager of North America, InspireMD has granted Mr. Ligotti 138,460 shares of restricted stock and stock options to purchase 46,150 shares of InspireMD’s common stock.

InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System

Retrieved on: 
Wednesday, December 20, 2023
NSPR, Bleeding, Risk, Physician, FDA, TCAR, TEL, Blood, Brain, Clinical trial, Stroke, Patent, NPS, IDE, Medicare, Patient, Safety, Stenosis, CAS, CMS, EPS, Pharmaceutical industry

TEL AVIV, Israel and MIAMI, Dec. 20, 2023 (GLOBE NEWSWIRE) -- InspireMD (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, announced today the issuance of U.S. Patent No.

Key Points: 
  • TEL AVIV, Israel and MIAMI, Dec. 20, 2023 (GLOBE NEWSWIRE) -- InspireMD (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, announced today the issuance of U.S. Patent No.
  • 11,844,893, titled, “Shunts with Blood Flow Indicators.”
    The patent covers key aspects of the company’s SwitchGuard™ Neuroprotection System (NPS) along with future features in development that are expected to enable the treating physician to visualize flow through the system.
  • The SwitchGuard™ NPS is designed to allow the physician to reverse blood flow to the brain during a carotid artery stenting procedure, including Transcarotid Artery Revascularization (TCAR) or other neurovascular procedures.
  • The broader availability of these less invasive options should better enable physicians to tailor treatment plans to the needs of individual patients.

InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions

Retrieved on: 
Monday, November 27, 2023
NSPR, Buffalo, Stroke, FDA, TEL, EFS, Stenosis, Prolapse, Stent, Thrombectomy, Growth, Patient, Safety, Plaque, State university system, EPS, Pharmaceutical industry

As a result, there are currently no FDA approved stents for this specific indication.

Key Points: 
  • As a result, there are currently no FDA approved stents for this specific indication.
  • Retrospective analyses from large centers across the globe have suggested the safety and efficacy of stenting in conjunction with intracranial thrombectomy.
  • I am also excited that this brings the carotid disease as it pertains to neurointerventionalists to the forefront.
  • The EFS is expected to enroll 15 patients across three U.S. trial sites and explore the safety and feasibility of using the CGuard EPS carotid stent, with its unique MicroNet™ mesh covering, to treat acute ischemic stroke patients with tandem lesions.

Silk Road Medical (SILK) Stock Tanks After Revenues Lowered and CEO Leaves – Hagens Berman

Retrieved on: 
Tuesday, November 21, 2023
NCD, TCAR, Hagens Berman, SAN, News, Stroke, Person, Silk Road, Stenosis, FY, SILK

SAN FRANCISCO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Hagens Berman encourages Silk Road Medical, Inc. (NASDAQ: SILK) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Hagens Berman encourages Silk Road Medical, Inc. (NASDAQ: SILK) investors who suffered substantial losses to submit your losses now .
  • On Oct. 10, 2023, Silk Road announced, without explanation, that: (1) its Q3 2023 revenues were expected to be below Q2 revenues; and (2) it significantly reduced its expected FY 2023 revenues.
  • This news drove the price of Silk Medical shares down nearly 50% on Oct. 11, 2023.
  • “We’re focused on investors’ losses and investigating whether Silk Road may have misled investors about the effect of the NCD’s decision on TCAR-related revenues,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

Neurology Devices Global Market Outlook to 2028, with Profiles of Medtronic, Abbott, Terumo, Boston Scientific Corp., Natus Medical and Siemens Healthineers - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 28, 2023
Medical Devices, Health, Surgery, Neurology, Radiology, Biotechnology, Patient, Quality of life, Boston Scientific, Alzheimer's disease, DSM-IV codes, Research, Aneurysm, Stenosis, Epilepsy, Multiple sclerosis, Prevalence, Neurodegenerative disease, Stroke, Parkinson's disease, Medtronic, Siemens Healthineers, Growth, Investment, Row, Diagnosis, Medical imaging

Aging Population: The growing worldwide elderly population is a significant driver of the neurology devices market.

Key Points: 
  • Aging Population: The growing worldwide elderly population is a significant driver of the neurology devices market.
  • The rising prevalence of these conditions and the increasing number of patients resistant to medication drive the demand for neurology devices.
  • Based on product type, the market is segmented into neurosurgical devices, neuromodulation devices, neurovascular devices and neurodiagnostic devices.
  • This report examines the factors driving growth in the neurology devices market, and it reviews major players, established companies, and new entrants.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Silk Road Medical, Inc. - SILK

Retrieved on: 
Monday, November 13, 2023
National coverage determination, Medicaid, LLP, Silk, Stenosis, Silk Road, Stroke, Medicare, News, Prior, Pomerantz, Cryptocurrency

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Silk Road Medical, Inc. (“Silk Road” or the “Company”) (NASDAQ: SILK).

Key Points: 
  • NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Silk Road Medical, Inc. (“Silk Road” or the “Company”) (NASDAQ: SILK).
  • The investigation concerns whether Silk Road and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • On October 10, 2023, Silk Road announced that its second quarter 2023 revenues were expected to be below its first quarter revenues and significantly reduced its expected full year 2023 revenues.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Silk Road Medical (SILK) Investors with Substantial Losses Encouraged to Contact Hagens Berman, National Trial Attorneys: Firm Investigating Possible Securities Law Violations

Retrieved on: 
Monday, November 13, 2023
Hagens Berman, Stroke, Person, NCD, TCAR, Stenosis, News, FY, SILK, Silk Road, Pharmaceutical industry

On Oct. 10, 2023, Silk Road announced, without explanation, that: (1) its Q3 2023 revenues were expected to be below Q2 revenues; and (2) it significantly reduced its expected FY 2023 revenues.

Key Points: 
  • On Oct. 10, 2023, Silk Road announced, without explanation, that: (1) its Q3 2023 revenues were expected to be below Q2 revenues; and (2) it significantly reduced its expected FY 2023 revenues.
  • “We’re focused on investors’ losses and investigating whether Silk Road may have misled investors about the effect of the NCD’s decision on TCAR-related revenues,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Silk Road Medical and have significant losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman .
  • Whistleblowers: Persons with non-public information regarding Silk Road Medical should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.

Vivasure Medical Announces First Patients Treated with PerQseal Elite Closure Device System

Retrieved on: 
Tuesday, December 12, 2023
Cardiology, Radiology, Surgery, General Health, Health, Medical Devices, Health Technology, Clinical Trials, TAVR, Safety, Calcium, Elite, ELITE, CAD, Aortic stenosis, Patient, Stenosis, EVAR, IDE, Trial of the century, TEVAR, Investigational device exemption

Vivasure Medical® , a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced the first patient treated with PerQseal® Elite, the latest generation of the company’s fully absorbable large-hole closure system.

Key Points: 
  • Vivasure Medical® , a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced the first patient treated with PerQseal® Elite, the latest generation of the company’s fully absorbable large-hole closure system.
  • Ph.D., at Erasmus University Hospital in Rotterdam, The Netherlands, as part of the company’s ELITE Study—a prospective, multi-center, single-arm clinical study evaluating the safety and efficacy of PerQseal Elite.
  • PerQseal Elite leverages the legacy PerQseal system’s excellent safety profile and ease of use.
  • The company continues to enroll patients for its Investigational Device Exemption (IDE) clinical study for PerQseal and PerQseal+ in the United States.